What Allgens does

Allgens Medical Technology Co., Ltd. (奥精医疗科技股份有限公司, ticker 688613.SH) is a publicly listed Chinese medical device company founded in 2004 and headquartered in Beijing, with manufacturing operations in Beijing Daxing and Shandong Weifang. The company specializes in regenerative medicine materials and implantable medical devices, built around a proprietary in vitro biomimetic mineralization technology that synthesizes ordered Type I collagen and nano-hydroxyapatite composites whose composition and microstructure closely mimic natural human bone matrix. This single technology platform is commercialized across three flagship product brands addressing distinct surgical specialties: 骼金/Hijin (BonGold™) for orthopedic bone defect repair, 颅瑞/Lurui (SkuHeal™) for neurosurgical cranial repair, and 齿贝/Chibei (OssaNova™) for dental and oral surgery, supplemented by a modular family of format-specialized sub-products (bone putty, membranes, plugs, extraction socket fillers, PMMA-modified bone powder, nail-channel filling rods) and a Type I collagen raw material line serving cosmetics, food supplements, and scientific research customers. Products are produced in Class-10,000 cleanroom facilities certified under ISO 13485 and are approved by China NMPA (three Class III registrations for orthopedics, stomatology, and neurosurgery), US FDA (510(k) clearance in 2015 — the first for a Chinese domestic artificial bone product), and the Indonesia and Malaysia ministries of health.

Allgens derives revenue primarily from hardware sales of medical devices to hospitals and distributors in China and select international markets, with cumulative clinical use exceeding one million cases across orthopedic, dental, neurosurgical, and plastic surgery indications. The go-to-market model combines direct regional sales managers covering specific Chinese provinces (e.g., Beijing, Shanghai, Guangdong, Jiangsu, Hubei, Gansu, Anhui, Guizhou) with a recruited distributor channel (national investment-attraction roadshows, e.g., Shenzhen 2023), supported by heavy participation in orthopedic and dental academic conferences (CMEF, COA, CAOS, BOA, Beijing International Dental Show) and satellite symposia to drive clinical adoption. International expansion is led by a Beijing/Wuhan-based overseas sales team and the 2024-acquired German subsidiary HumanTech Dental GmbH (HT Dental), with active distribution development in Southeast Asia (Indonesia, Malaysia), the United States, Latin America, the Middle East, and Africa. The company is led academically by founder and Chief Scientist Cui Fuzhai (Tsinghua professor, AIMBE Fellow, National Natural Science Second Prize recipient) and operationally by Chairman Hu Gang and General Manager Cui Menglong, with the founder-led structure and government industrial capital backing (Zhongguancun Development Group, Weifang High-Precision Equity Investment Fund) underpinning its R&D-driven positioning.

Name

Allgens

Legal name

奥精医疗科技股份有限公司 (Allgens Medical Technology Co., Ltd.)

Website

https://allgensmed.cn

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

Allgens Medical is a Beijing-based, STAR Market-listed medical device company that develops and commercializes proprietary mineralized collagen biomimetic bone repair materials and collagen-based implants for orthopedic, neurosurgical, dental, and plastic surgery departments in hospitals across China and select international markets.

Ownership category

akta.pro rank

Product category

Orthopedic Biomaterials / Regenerative Medical Devices

NAICS

Dental Laboratories (339116), Dental Equipment and Supplies Manufacturing (339114)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Dental Equipment & Supplies (3843)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Dental Implants & Prosthodontic Components (Implants/Abutments/Prosthetics) (HLAHAEAE), Full-Mouth Rehabilitation & Complex Restorative Care (HLABAFAD)

Keywords

• Regenerative bone repair materials
• Mineralized collagen implants
• Orthopedic bone substitutes
• Dental bone regeneration
• Neurosurgical bone repair

Headquarters

HQ city

Haidian

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Medical device product sales (硬件销售): Core revenue stream from sale of mineralized collagen biomimetic bone repair materials (骼金, 颅瑞, 齿贝, etc.), collagen raw materials, and customized implant products to hospitals, distributors, and OEM customers in China and internationally; clinical use exceeded 1 million cases. Includes standard product line and customized high-strength implants for pediatric/cranial applications.
2. Collagen raw material and OEM/private-label supply (胶原原料/代工): Supply of Type I collagen raw materials and collagen-derived OEM/contract-manufacturing services for cosmetics, medical aesthetics, medical devices, and academic research customers.
3. Acquisition-driven international revenue (German subsidiary HT Dental): Revenue contribution from 100% acquisition of German HumanTech Dental GmbH (HT Dental), focused on dental implant medical devices development and sales; transaction valued at approximately EUR 3.246 million and expected to close in Q2 2024.

Go-to-market motion5 records

Distribution channels5 records

Marketing channels9 records

Core offering

Allgens develops, manufactures, and sells mineralized collagen biomimetic bone repair materials and related implantable medical devices for orthopedic, dental/oral, neurosurgical, and plastic surgery bone defect repair. The core technology is a proprietary in vitro biomimetic mineralization process that produces ordered Type I collagen + nano-hydroxyapatite composites whose composition and microstructure closely mimic natural human bone. Products are sold in China through direct sales managers and regional distributors to Class III hospitals, with international sales via a German subsidiary and overseas distributors.

Product overview

Allgens Medical operates a single unified technology platform built around proprietary bionic mineralized collagen (Type I collagen + nano-hydroxyapatite composite) synthesized via in-vitro biomimetic mineralization. The portfolio is organized as one core platform expressed through three flagship brand products addressing different surgical specialties: 骼金/Gaikin (BonGold™ overseas) for orthopedics, 颅瑞/Lurui (SkuHeal™ overseas) for neurosurgery, and 齿贝/Chibei (OssaNova™ overseas) for dental/oral surgery. Around this core, the company offers a modular family of format-specialized sub-products — including 骨融合膜 (bone fusion membrane), 人工骨膜 (artificial bone membrane), 人工骨泥 (artificial bone paste in both orthopedic and neurosurgical variants), 颅骨修补塞 (skull repair plug), 填充仿生骨 (filling bionic bone), 矿化胶原骨粉 (mineralized collagen bone powder), 矿化胶原骨膜 (mineralized collagen bone membrane), 拔牙窝填充塞 (tooth extraction socket filler), PMMA改性骨粉 (PMMA modified bone powder for bone cement), 仿生骨-普通强度颗粒/块 and 仿生骨-中等强度颗粒/块 (normal and medium strength bionic bone granules/blocks), and 钉道填充棒 (nail channel filling rod) — plus a standalone Type I 胶原蛋白 (Collagen) raw material product line for cosmetic, food, and scientific research use, and a separately approved 可吸收胶原蛋白止血海绵 (absorbable collagen hemostatic sponge). Products are produced in two cleanroom facilities (Beijing Zhongguancun and Shandong Weifang Health Industrial Park) and certified under ISO 13485 with China NMPA Class III registrations, US FDA 510(k), and Indonesia/Malaysia MOH registrations.

Differentiator

Problem solved

Functional benefit

Brands

• 骼金® (Hijin): Artificial bone repair material (mineralized collagen biomimetic bone) for orthopedic bone defect repair; the flagship Class III medical device product.
• 颅瑞® (Lunrui)
• 齿贝 (Chibei)
• BonGold™
• OssaNova™
• SkuHeal™
• Allgens

Products and services

• 骼金 (Hijin / BonGold™) - Artificial Bone Repair Material for Orthopedics Bionic mineralized collagen artificial bone repair material composed of orderly arranged Type I collagen and nano-hydroxyapatite (HA) composite, with composition and microstructure highly similar to natural bone matrix. Synthesized via proprietary in vitro biomimetic mineralization technology, fully biodegradable in vivo, and guides new bone formation. Holds China NMPA Class III medical device registration (2011) and US FDA 510(k) clearance (2015, as BonGold™). Registered with Indonesia MOH (2024) and Malaysia (August 2024). Widely used in orthopedic bone defect repair across fracture repair, delayed/non-union, spinal fusion, and benign bone tumor applications; clinical use exceeded 1 million cases cumulatively.
• 颅瑞 (Lurui / SkuHeal™) - Artificial Bone Repair Material for Neurosurgery Bionic mineralized collagen artificial bone repair material designed for cranial/neurosurgical applications, featuring the same biomimetic composition of Type I collagen and nano-hydroxyapatite as the core platform. Fully degradable and absorbable in vivo, with osteoconductive activity matching natural bone regeneration. Holds China NMPA Class III medical device registration for neurosurgery (2014), and is registered with Indonesia MOH in 2024 as SkuHeal™ for neurosurgery applications. Used for cranial defect repair after craniotomy burr holes, microvascular decompression (MVD) small bone window repair, and traumatic small skull defects.
• 齿贝 (Chibei / OssaNova™) - Artificial Bone Repair Material for Dental/Oral Surgery Bionic mineralized collagen artificial bone repair material tailored for dental and oral surgical applications, with the same biomimetic composition and structure as the core platform. Fully biodegradable in vivo, guides new bone formation, and promotes healing of oral bone defects. Holds China NMPA Class III medical device registration for dental/oral and plastic surgery (2014), and is registered with Indonesia MOH in 2024 as OssaNova™ for dental/oral/plastic surgery indications. Used in dental implantology, periodontal bone defect repair, tooth extraction socket preservation, sinus lift, and peri-implantitis bone regeneration.
• 胶原蛋白 (Type I Collagen) - Raw Material / OEM Supply Type I collagen purified from bovine tissue compliant with ISO 22442 and YY/T 0771 series standards via enzymatic cleavage and purification, with C- and N-terminal immunogenic epitopes removed and the active triple-helix structure preserved. Low antigenicity and immunogenicity, good biocompatibility, fully absorbable, hydroxyproline content approximately 11% of total protein. Available in customizable forms (gels, solutions, powders, flocs, sheets). Applications include cosmetics (masks, creams), food (oral liquids, beverages, supplements), and scientific research (tissue engineering scaffolds, cell culture carriers, drug carriers). Sold as a B2B raw material product with OEM/private-label services.
• 可吸收胶原蛋白止血海绵 (Absorbable Collagen Hemostatic Sponge) Absorbable collagen hemostatic sponge that received China NMPA regulatory approval in 2023, leveraging Allgens' core Type I collagen raw material expertise to expand the company's collagen-based product portfolio beyond bone repair into hemostasis applications.

Quantifiable outcome

• Cumulative clinical use exceeded 1 million cases in orthopedics, dentistry, neurosurgery, and plastic surgery
• +6 more outcomes

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

19 partnerships are on record, tiered flagship, core and minor.

• HumanTech Dental GmbH (HT Dental)flagshipStrategic or Co-development PartnerAllgens Medical acquired 100% of German HumanTech Dental GmbH (HT Dental) for approximately EUR 3.246 million to expand into dental implant medical devices. The transaction is expected to close in Q2 2024 subject to regulatory approval. HT Dental is based in Stuttgart, Germany, and focuses on the development and sales of dental implant medical devices. Post-acquisition, the management team and all employees of HT Dental are retained.
• Hebei University of Technology (河北工业大学)flagshipStrategic or Co-development PartnerCo-lead partner with Allgens Medical for the '14th Five-Year Plan' National Key R&D Program 'Personalized Cranial Biomimetic Composite Repair Material with Guided Bone Regeneration Function' project, with Professor Yang Lei of Hebei University of Technology's School of Life Sciences and Health Engineering as project lead. Project received CNY 12 million national funding and was officially launched on January 19, 2024 at the First Medical Center of Chinese PLA General Hospital.
• Tsinghua University (清华大学)flagshipStrategic or Co-development PartnerLong-term research partner. Tsinghua University (School of Materials Science and Engineering) jointly established the 'Regenerative Medicine Materials Joint Research Center' with Allgens Medical. Tsinghua Professor Wang Xiumei is principal investigator for the '13th Five-Year Plan' National Key R&D Program on pediatric bone defect regeneration. Joint 14th Five-Year Plan project (cranial repair) also involves Tsinghua University and its affiliated Beijing Tsinghua Changgung Hospital as participating units.
• Capital Medical University Affiliated Beijing Children's Hospital (首都医科大学附属北京儿童医院)coreStrategic or Co-development PartnerClinical research partner led by Director Wang Qiang for Project 4 'High-Strength Mineralized Collagen Biomimetic Bone Repair for Pediatric Segmental Long Bone Defects'. Enrolled 32 patients (3-15 years), demonstrated bone density reaching 92.7% of normal at 6 months post-op.
• Peking University Hospital of Stomatology (北京大学口腔医院)coreStrategic or Co-development PartnerClinical research partner for Project 3 of the '13th Five-Year Plan' National Key R&D Program on pediatric alveolar cleft repair; led by Professor Ma Lian (Director of Cleft Lip and Palate Center). 37 patients enrolled (ages 8-12), with bone density reaching 81% of surrounding bone at 6 months post-op.
• Chinese PLA General Hospital (中国人民解放军总医院)coreStrategic or Co-development PartnerCo-lead participating unit and site of project launch ceremony (First Medical Center) for the 14th Five-Year Plan cranial repair project; expert Prof. Guo Quanyi. Also a long-term collaboration partner.
• Sun Yat-sen University (中山大学)coreStrategic or Co-development PartnerParticipating unit of the 14th Five-Year Plan cranial repair project led by Professor Liu Jie; also independent clinical research collaborator. Professor Zou Xuenong from Sun Yat-sen University First Affiliated Hospital served as a project review expert.
• Wenzhou Medical University Affiliated Second Hospital (温州医科大学附属第二医院)coreStrategic or Co-development PartnerParticipating unit of the 14th Five-Year Plan cranial repair project; led by Director Lin Jian.
• Beijing University of Science and Technology (北京科技大学)coreStrategic or Co-development PartnerParticipating unit of the 14th Five-Year Plan cranial repair project.
• Shanghai University (上海大学)coreStrategic or Co-development PartnerParticipating unit of the 14th Five-Year Plan cranial repair project.
• Wuhan University of Technology (武汉理工大学)coreStrategic or Co-development PartnerParticipating unit of the 14th Five-Year Plan cranial repair project.
• Wuhan Asia Biomaterials Co., Ltd. (武汉亚洲生物材料有限公司)minorStrategic or Co-development PartnerParticipating unit of the 14th Five-Year Plan cranial repair project as one of ten collaborating research institutions and medical device enterprises.
• Beijing Zhongguancun Shangdi Biotechnology Development Co., Ltd. (北京中关村上地生物科技发展有限公司)minorStrategic or Co-development PartnerChairman Liu Rongyao attended and delivered a speech at the 14th Five-Year Plan project launch ceremony.
• Hangzhou Yujie Medical Technology Co., Ltd. (杭州予捷医疗科技有限公司)minorChannel Partner/ Reseller/ DistributorRegional distributor that co-organized the Zhejiang orthopedic annual meeting satellite symposium on 'BoneGold Artificial Bone Repair Material and Clinical Application' in September 2018.
• Antonios G. Mikos (Rice University, US National Academy of Engineering, US National Academy of Medicine)flagshipStrategic or Co-development PartnerInternational biomaterials expert serving on the expert committee of the Weifang Allgens Regenerative Medicine Materials International Research Institute. Professor Mikos attended the groundbreaking ceremony of the Weifang International Health Tech Industrial Park in 2018 and was appointed as expert committee member.
• In-Soep Lee (Yonsei University, Korea; Vice Chairman of Korean Society for Biomaterials)coreStrategic or Co-development PartnerInternational biomaterials expert serving on the expert committee of the Weifang Allgens Regenerative Medicine Materials International Research Institute; appointed as expert committee member during 2018 groundbreaking ceremony.
• Yang Lei (Hebei University of Technology, appointed as Allgens Chief Scientist for 14th Five-Year Plan)flagshipStrategic or Co-development PartnerProfessor Yang Lei of Hebei University of Technology's School of Life Sciences and Health Engineering was formally appointed as 'Top-level Expert' and Chief Scientist of the 14th Five-Year Plan special project by Allgens General Manager Cui Menglong at the project launch ceremony in January 2024.
• Antonios G. Mikos, Wang Xiumei, In-Soep Lee - Weifang Allgens Regenerative Medicine Materials International Research Institute expert committeeflagshipStrategic or Co-development PartnerJoint establishment of Weifang Allgens Regenerative Medicine Materials International Research Institute with Tsinghua University Professor Wang Xiumei as院长 (Director). Brings together US National Academy Engineering/Medicine Member Mikos, Yonsei University Biomaterials VP Lee, and Tsinghua research team for advanced biomaterials technology incubation.
• German HumanTech AG (德国优曼泰克股份有限公司)coreStrategic or Co-development PartnerSigned Sino-European high-end medical device international cooperation agreement on January 18, 2019 at Junhan International Hotel; Deputy GM Nico introduced the cooperation project. Co-signing as part of Allgens' global expansion into the European high-end orthopedic medical device market.

Scale indicators15 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Medtronic: Global medical device leader with spine (Infuse BMP bone graft), cranial, and neurosurgery franchises. Competes with Allgens in spinal fusion bone graft substitutes and cranial repair; differs in scale, breadth, and use of growth-factor-based grafts versus mineralized collagen.
• Stryker: US-listed global medical device incumbent with extensive orthopedic trauma, spine, joint reconstruction, and surgical equipment portfolios. Competes broadly with Allgens in orthopedic bone repair and spine fusion markets, though Allgens's biomimetic collagen platform differs from Stryker's traditional allograft and synthetic offerings.
• Wright Medical (Smith+Nephew): Smith+Nephew acquired Wright Medical in 2020, combining upper extremity, foot/ankle, and biologics (including bone graft substitutes) franchises. Competes with Allgens in extremity and trauma bone repair, with BonGold specifically targeting foot/ankle clinical use in the US.
• Danaher: US-listed diversified life sciences conglomerate that owns Nobel Biocare (now under Envista) and other dental/orthopedic assets. Comparable as a global dental implant and regenerative materials platform with much greater commercial reach and R&D budget than Allgens.
• Zimmer Biomet: US-listed global orthopedic device incumbent covering joint reconstruction, trauma, spine, and dental. Overlaps with Allgens in bone defect repair for trauma, fracture, and spine fusion indications, though distribution scale and capital intensity are far greater.
• Straumann: Swiss-listed global leader in dental implants and a growing regenerative dentistry business (bone graft substitutes, membranes). Directly comparable to Allgens's dental product line (OssaNova/Chibei) and to the newly acquired HumanTech Dental business.

Direct peers

• Integra LifeSciences: US-listed medical device company with a regenerative tissue technologies portfolio (DuraGen, Integra dermal regeneration templates) and neurosurgery/cranial repair products. Directly comparable to Allgens's cranial repair and collagen-based regenerative materials lines and serves the same tertiary hospital surgical departments.
• Yantai Zhenghai Bio-tech: Chinese A-share listed (300653.SZ) developer of collagen-based regenerative medical devices including dental membranes, bone repair materials, and skin repair products. Most directly comparable Chinese peer, competing in dental/oral bone regeneration membrane market with overlapping NMPA Class III registrations.
• Geistlich Pharma: Swiss private company that is the global leader in dental bone regeneration with its Bio-Oss and Bio-Gide products, both xenogeneic bone graft substitutes. Comparable to Allgens in dental bone graft substitute category, with much larger global market share in the same dental/oral indications.

Emerging players

• CollPlant Biotechnologies: Israel/US-listed regenerative medicine company developing recombinant human collagen and 3D-bioprinted regenerative implants for orthopedics and tissue engineering. Emerging peer in collagen-based regenerative materials with overlapping technology approach (Type I collagen-based scaffolds) though currently focused on soft tissue and large defect indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/yijiabao

Compliance20 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allgens